FDA Inspection
AbbVie Inc.AbbVie Inc. – FDA Inspection, Jul 2, 2018
Record Details
This FDA Inspection record concerns AbbVie Inc., with an inspection on July 2, 2018, issued by the Center for Drug Evaluation and Research, covering drugs.
- Person
- Lequita M. Mayhew (Issuing Officer)
View Company Profile
ID · eaf4e346-ae49-45b5-8099-233eb6e1411c
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1058302
- FDA center
- Human Drugs
- Project area
- Bioresearch Monitoring
- Outcome
- Form 483 issued
FDA Citations
1- 21 CFR 314.80(c)(1)(i)Late submission of 15-day report
Full citation text and observation details available on the Dashboard.
Other FDA inspections of AbbVie Inc.
21| Date | Classification | Office | Project area |
|---|---|---|---|
| April 27, 2026 | Not classified | Chicago District Office | |
| April 2, 2026 | Not classified | Chicago District Office | |
| August 21, 2025 | Not classified | Chicago District Office | |
| June 12, 2025 | NAI | Center for Biologics Evaluation and Research | Bioresearch Monitoring |
| February 18, 2025 | Not classified | Chicago District Office |
Other documents for AbbVie Inc.
- FDA Inspection 1299008 - 2026-04-27
- FDA Inspection 1302298 - 2026-04-02
- FDA Inspection 1277010 - 2025-08-21
- FDA Inspection 1257605 - 2025-06-12
- FDA Inspection 1230795 - 2025-02-18
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.